Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 31, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per share. The Company's...
Oct 19, 2017 Overall revenue of $3.5M is up 5% year-over-year Quell shipments of 15.6K devices are up 29% year-over-year Quell shipments of 28.7K electrode reorders are up 99% year-over-year Capital structure was simplified with 86% of outstanding warrants ...
Oct 10, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19, 2017 to discuss its ...
Sep 5, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) today announced it will be a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York Palace Hotel ...
Aug 31, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the upcoming PAINWeek national conference to be held in Las Vegas, NV, September 5-9. Both studies leveraged the Quell® Health Cloud, which connects with t...
Aug 29, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. (Nasdaq: NURO) is partnering with the U.S. Pain Foundation, a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the issues im...
Aug 15, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell® device automatically modulates therapeutic neurostimulation based on the user's sle...
Aug 3, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement with Fukuda Denshi for DPNCheck® distribution in Japan. DPNCheck is NeuroMetrix' rapid, accurate, and quantitative point-of-care test to detect diabetic peripheral neuropathy. Diabetes is a serious health ...
Jul 27, 2017 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000th Quell® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has been on...
Jul 20, 2017 Revenue of $4.3M is up 63% year-over-year Quell device shipments of 20.1K and electrode reorders of 30.7K represent new quarterly highs DPNCheck revenue of $0.8 million is up 78% year-over-year WALTHAM, Mass.--(BUSINESS WIRE)-- ...
Jul 13, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 second quarter financial results before the opening of the market on Thursday July 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on July 20, 2017 to discuss its ...
Jul 10, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000 shares of Series F convertible preferred stock at a price ...
Jul 6, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company's diagnostic products which include DPNCheck® and ADVANCE™. ...
Jun 26, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell® Health Cloud. Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning a...
Jun 23, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell® clinical program. Quell is a wearable non-invasive neurostimulator that provides widespread analgesia for chronic pain. In addition to delivery of therapy, the device and its associated smartphone app tr...
Page:
2
...
21
Next Last
 
= add release to Briefcase